Irbegen

Irbegen

irbesartan

Manufacturer:

Genepharm

Distributor:

Firma Welfare Instrument
/
SB Pharma
Concise Prescribing Info
Contents
Irbesartan
Indications/Uses
Essential HTN. Protection of kidney in patients w/ high BP, type 2 DM & laboratory evidence of impaired kidney function.
Dosage/Direction for Use
High BP 150 mg once daily. May be increased to 300 mg once daily depending on BP response. High BP & type 2 DM w/ kidney disease 300 mg once daily. Dose may be lowered initially in patients on haemodialysis, or elderly >75 yr.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Concomitant use w/ medicines containing aliskiren in patients w/ diabetes or impaired kidney function (GFR <60 mL/min/1.73 m2). Pregnancy (>3 mth).
Special Precautions
Dual blockade of renin-angiotensin-aldosterone system through combined use of ACE inhibitors, AIIAs or aliskiren is not recommended. Patients suffering from excessive vomiting or diarrhoea; heart problems; undergoing surgery or receiving anaesth. Perform regular blood tests, especially for measuring blood K levels in case of poor kidney function in patients w/ diabetic kidney disease. Check kidney function, BP, & amount of blood electrolytes (eg, K) at regular intervals. Lactose intolerance. Occasional dizziness or weariness may occur during treatment. Kidney problems. Pregnancy & lactation. Childn & adolescents.
Adverse Reactions
Dizziness, feeling sick/vomiting, fatigue & raised levels of creatine kinase. High BP & type 2 DM w/ kidney disease: Increased level of K. Dizziness & low BP when getting up from a lying or sitting position, pain in joints or muscles, decreased Hb levels.
Drug Interactions
Higher frequency of adverse events (eg, hypotension, hyperkalaemia & decreased renal function including acute renal failure) in combined use w/ ACE inhibitors, AIIAs or aliskiren. Blood checks may be needed when taking K supplements; salt substitutes containing K; K-sparing medicines (eg, certain diuretics); medicines containing lithium. Reduced effect w/ NSAIDs.
ATC Classification
C09CA04 - irbesartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
Presentation/Packing
Form
Irbegen FC tab 150 mg
Packing/Price
2 × 15's
Form
Irbegen FC tab 300 mg
Packing/Price
2 × 15's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in